A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC

NCT05212922 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Sponsor Decision

Conditions

HCC
NSCLC Stage IIIB
NSCLC Stage IV

Interventions

DRUG: YH001 + Toripalimab

Sponsor

Eucure (Beijing) Biopharma Co., Ltd